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Abstract
Background: Systematic approach for drug discovery is an emerging discipline in systems biology research area. It
aims at integrating interaction data and experimental data to elucidate diseases and also raises new issues in drug
discovery for cancer treatment. However, drug target discovery is still at a trial-and-error experimental stage and it
is a challenging task to develop a prediction model that can systematically detect possible drug targets to deal
with complex diseases.
Methods: We integrate gene expression, disease genes and interaction networks to identify the effective drug
targets which have a strong influence on disease genes using network flow approach. In the experiments, we
adopt the microarray dataset containing 62 prostate cancer samples and 41 normal samples, 108 known prostate
cancer genes and 322 approved drug targets treated in human extracted from DrugBank database to be candidate
proteins as our test data. Using our method, we prioritize the candidate proteins and validate them to the known
prostate cancer drug targets.
Results: We successfully identify potential drug targets which are strongly related to the well known drugs for
prostate cancer treatment and also discover more potential drug targets which raise the attention to biologists at
present. We denote that it is hard to discover drug targets based only on differential expression changes due to
the fact that those genes used to be drug targets may not always have significant expression changes. Comparing
to previous methods that depend on the network topology attributes, they turn out that the genes having
potential as drug targets are weakly correlated to critical points in a network. In comparison with previous
methods, our results have highest mean average precision and also rank the position of the truly drug targets
higher. It thereby verifies the effectiveness of our method.
Conclusions: Our method does not know the real ideal routes in the disease network but it tries to find the
feasible flow to give a strong influence to the disease genes through possible paths. We successfully formulate the
identification of drug target prediction as a maximum flow problem on biological networks and discover potential
drug targets in an accurate manner.
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Cancer is extremely complex and it is viewed as a multi-
stage disease caused by the accumulation of genetic
alterations in tumor associated suppressor oncogenes
[1]. It is a fundamental challenge in human health to
understand disease mechanisms for diagnosis. In phar-
macology and e-health research area, drugs play key
roles to cure a disease and drug research focuses more
on identification of the drug targets which can be
manipulated to produce the desired effect with disease
g e n e s[ 2 , 3 ] .B u t ,t h et h e r a p i e su s e dn o w a d a y sa g a i n s t
cancers are not effective and it is also extremely impor-
tant to understand the underlying significant networks
and mechanisms in order to prevent the progression of
the tumor. Systems medicine is an emerging approach
in systems biology that aims at integrating a large scale
of the molecular interaction data and experimental data
to elucidate diseases and drugs associations [4,5]. There-
fore, identifying the potential set of drug targets to elim-
inate the disease genes and related networks is a
valuable problem for drug design.
The traditional computational approaches utilize
structural information to predict whether a protein can
be a drug target [6]. Although these methods achieved
reasonable performance, they suffer from limited avail-
ability of data such as protein 3D structures. Several
algorithms have been proposed to predict drug-target
associations by combining drug-drug and gene-gene
similarity measurement [7-9]. Chemical structure of the
drugs and sequence information of the target proteins
were used to be the features to learn the classifier based
on the target proteins as gold-standard positive dataset.
However, the two dimensional chemical structure does
not always comply with three-dimensional structural
similarity [10]. Beside the sequence, structure-based
approach, biological networks and functional annota-
tions help us to understand the complexity of the cell.
B a k h e e te ta l .p r o p o s e dal i s to fp r o p e r t i e so fh u m a n
drug target proteins, including EC numbers, Gene
Ontology (GO) term as features to predict potential
drug targets [11]. However, GO terms include a brief
description of the corresponding biological function of
the genes but only 60% of all human genes have asso-
ciated GO terms and these terms may be inconsistent
due to differences in curators’ judgment [12]. Based on
the different features to predict the potential drug target
must have the positive and negative data to build the
accurate prediction model. But, it is technically difficult
to determine negative data such like non-drug targets
due to the lack of researchers who are interested in vali-
dating them. However, all of the above methods focus
more on prediction the drug-target interactions which
predict possible target proteins of drugs with unknown
targets. Their approaches did not directly predict the
potential protein which can be a drug target for a speci-
fic disease treatment.
The complex biological system is assembled and com-
municated with a set of interacting elements which are
bound together by the interactions. Scale-free biological
n e t w o r k sh a v eaf e wn o d e sw i t hav e r yl a r g en u m b e ro f
links (degree) and many nodes have only a few links
[13]. This implies that the low-degree nodes may belong
to the sub-networks which tend to form communities
and those sub-networks are connected to each other
through high degree nodes (hubs). It implies that the
sparsely connected nodes in the network are part of
highly clustered regions with communication and there
is minimum number of steps from a given gene to the
other genes. This event also denotes that a given genes
can grow rapidly to the other communities by the hub
connection which suffers from the small world effect
[13]. Based on the characteristic of biological network, it
provides a framework for understanding the pathophy-
siological phenomena and network-based analysis aims
to harness this knowledge to understand the impact of
intervention [14]. We explore computational strategies
for identifying drug target, aiming to identify important
nodes in the network. The bridge-elements of biological
networks such as nodes with higher degree can be
important targets of network-based drug discovery [14].
Hubs with higher degree nodes are the centre of net-
works only from the point of local network topology
and thus their removal may disrupt a number of essen-
tial pathways to break cancer network. This method
takes all the interaction into consideration but they do
not further select active interaction relationships among
proteins while only a part of the interactions among a
set of proteins may be active at a specific condition [15].
Another strategy considers more global attribute such as
closeness/betweenness centrality and a node with higher
value of closeness/betweenness centrality would be
interpreted as initial candidates for drug targets [16]. A
common criticism of those global attributes that they
are measured based on the shortest paths and they do
not take into account non-shortest paths while spread-
ing the information in the network. Those global mea-
sures recently have a variation based on network flow
which has been proposed in [17]. On the other hand,
given the set of the essential disease-related pathways
and complexes, Hormozdiari applied the graph cut
approaches to disrupt all the paths which can communi-
cate with those essential pathways [18]. But we have
limited or even no information about the real possible
disease-related pathways.
Now, computational methods become increasingly
attracting the attention of biologists who wish to
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known the real ideal routes in the biological network,
gene expression will depend upon the mechanism as a
consequence of action through regulatory adjustments
as well as the changes it induces in the cell. Therefore,
our idea is to gather the knowledge of the interaction
networks and gene expression data to develop a network
flow-based approach for potential drug target discovery
which can produce strong effect on the disease genes.
Methods
We first define our method as input a set of candidate
proteins set C (known to be drug targets of the approved
drugs treated in human), disease genes set D (known to
be associated with the specific disease of interest). The
mutations of the genes lead to increase or decrease in
their gene expressions and the change of the protein
functions and this information can help us to identify the
new drug target for therapeutic intervention. Rapid iden-
tification of the drug targets needs to understand the
underlying essential functional networks modulated by
the transcription factors which may be affected by
human diseases [19,20]. Take an example in Figure 1,
gene 5 is regulated by transcription factor 9 in nucleus
and translates to the protein 5 and protein 5 interacts
with other proteins in cytoplasm. The dash line presents
the possible paths after the drug treatment for disease
gene 12. Subsequently, we integrate protein-protein and
protein-DNA interactions and assign weight values of
interactions based on the Pearson correlation and expres-
sion changes between experimental and control data. We
present a network flow approach to infer the relationship
between candidate proteins and disease genes. The aim
of this problem is to rank the proteins in C based on the
influenced effects of the disease genes D.
Microarray data pre-processing
Gene expressions either over-expressed or under-
expressed can be revealed in terms of two colored chan-
nel in the microarray data representing the intensity of
the developmental stage such as cancer and normal
samples. The gene expression ratios are calculated as
the median value of the pixels minus background pixel
median value for one color channel divided by the same
for the other channel. We extract the median value of
the log base 2 of each gene in experimental dataset
because the median value of the normalized ratio is
much harder to be affected by noise than the mean
value. In order to get as complete data as possible, we
use the K Nearest Neighbors (KNN) algorithm [21] to
estimate the missing values. There are 11130 genes after
removing genes that have more than 20% missing values
in the microarray dataset.
Edge weighted network construction from microarray
data and public interaction databases
Protein-protein interaction (PPI) networks are the
assembly of the protein signal cascades that transfer the
biological function and information through the path-
ways [22]. Current public PPI databases provide rich
information and they mostly differ on the way they
acquire or validate their data. For example, HPRD,
BIND, MINT and MIPS are manually curated, this
means a team of biologists check the literature to find
new interactions and once an interaction is confirmed it
is added to the database. On the other hand, DIP and
IntAct are based on literature mining and they achieve
these using computational methods that retrieve the
interaction knowledge automatically from published
papers. Prieto and De Las Rivas have shown a limited
intersection and overlap between the six major data-
bases (BioGRID, BIND, MINT, HPRD, IntAct, DIP)
[23]. The information contained in these databases is
partly complementary and the knowledge of the protein
interactions can be increased and improved by combin-
ing multiple databases. We integrate PPI data warehouse
with those six major databases and erase the duplicated
interaction pairs using the synonym of the protein
name. We map the synonym of the protein name and
then we erase the duplicated interaction pairs and suc-
cessfully gather 54283 available and non-redundant PPI
pairs among 10710 proteins [24]. Due to the limitation
of the knowledge of the directed interactions between
transcription factors and genes under specific condition,
we gather the associated interactions under prostate
cancer developed by Yeh et al. who used statistical
assessments to construct directly regulatory associations
between transcription factors and genes based on the
gene expression data and transcription factor binding
site prediction toolkit [25]. They have already
Figure 1 the biological networks containing gene regulation
and signal transduction [20].
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tors (PBX1, EP300, STAT6, SREBF1, NFKB1, STAT3,
EGR1, E2F3, NR2F2) and their regulatory networks and
validated by public literature and databases [25]. Finally,
we collect 13363 directed edges and 20567 bi-direction
edges as our network.
T h eh u m a ni n t e r a c t o m en etwork will be much more
biologically insightful while the microarray expression
data is taken into consideration. We assume that a pro-
tein interaction participates in a signaling pathway and
the genes producing the associated proteins should be
co-expressed and might be co-regulated. Grigoriev
showed that biologically relevant interacting proteins
have high mRNA expression correlations and the corre-
lation of the expression genes provides some evidences
and biological needs for the produced proteins in the
co-expression network linked in PPI [26]. Co-expression
networks are most commonly used for identifying cellu-
lar networks and the expressions of genes in co-expres-
sion networks are highly to form functional network
modules [27]. Those networks are built on the expres-
sion profile similarity measure which is often calculated
by Pearson correlation [27] and the correlation can mea-
sure the strength of a linear relationship between two
expression values of the genes in the microarray data.
Due to the drug target is treated in cancer network, we
apply Pearson correlation coefficient for every pair-wise
relation in the set of (N
2-N)/2 pairs of N genes in can-
cer data and the range of the value would be [-1,+1]. In
general statistical usage, the positive value in Pearson
correlation indicates an increasing linear relationship
and negative value indicate a decreasing linear relation-
ship. While the correlation is closer to +1 or -1, it
denotes the perfect linear relationship between pair of
genes. On the other hand, the correlation approaches to
zero and there would be little or no association among
the pair of genes. We take the absolute value of correla-
tion value to capture inhibitory activity (negative corre-
lation) as well as activation activity (positive correlation).
Therefore, we define the edge capacity in Equation (1)
as the product of the absolute value of Pearson correla-
tion Rij and the sum of the absolute value of differential
expression changes between the normal and the cancer
microarray data of the two corresponding genes i and j
in the edge.
we = wij =

Rij

 ×

|Eci − Eni| +

Ecj − Enj


(1)
where wij denotes the capacity function from edge e of
node i to node j. |Rij| is the absolute value of Pearson
correlation coefficient for the interaction of the node i
and node j from cancer samples. The higher weight of
pair of genes denotes the stronger correlation and differ-
ential expression exchanges between any two of the
genes. One the other hand, the weight is zero indicates
the two proteins are uncorrelated and no flow can pass
through. Eci i st h ea v e r a g eg e n ee x p r e s s i o nv a l u eo f
node i in the cancer microarray data and Eni represents
the average expression value in the normal microarray
data.
The network flow approach to discover the drug target
We gather 322 known drug targets treated in human
extracted from DrugBank [28] database to be candidate
proteins and 108 disease genes from curated database
OMIM ID #176807 [29], KEGG pathway database with
entry hsa05215 [30], PGDB database [31] as truly pros-
tate cancer genes see Additional file 1. We identify our
problem of discovering potential drug targets as a maxi-
mal flow problem that is to find out the amount of
flows that can pass between candidate proteins C and
the disease genes D in the networks. Maximizing the
flow amount from the candidate proteins to the disease
genes is reasonable because the efficiency in the biologi-
cal networks can award a treatment advantage to the
disease.
We make the following constraints to specify our pro-
blem into the classical maximum flow problem [32,33]:
(1) Constraints 1: The edge of a transcription regula-
tor gene to its dependent genes is directed while a PPI
is a bi-direction edge.
(2) Constraints 2: We create a dummy sink node
which links to all possible disease-causing genes based
on the public databases and the capacities on these
edges are all set to infinite.
(3) Constraints 3: We create a dummy source node
which links to one of the candidate proteins from the
DrugBank database [28] and the capacities on these
edges are set to infinite.
( 4 )C o n s t r a i n t s4 :I fad i s e a s eg e n ei sa l s oac a n d i d a t e
protein, we only link this gene to dummy source node
and do not link to the dummy sink node. Because it is
not fair to link the known disease genes to dummy sink
nodes which have an infinite flow.
According to the above constraints, we define human
interactome network as an edge-weighted graph G = (V,
E, W), where vertex u, v belong to V-{s,t}, V is a node
set of genes, s and t are source and sink nodes respec-
tively and E is an edge set and each edge (u, v)Î E, and
W is a non-negative capacity on the edges calculated by
Equation (1). This is different from the well-studied
maximum-flow problem in which the capacity of each
edge is a constant. The flow in a graph is dependent on
the capacity of the edge and it must satisfy the following
three conditions in order to find the maximum amount
of flow from the source node to the sink node through
the network [32,33]:
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to V, f (u,v) is termed the flow from node u to node v.
The property says that the reverse flow is the same
amount but in reversed direction.
(2) Capacity constraint: c(u,v) > f (u,v), for all u,v
belong to V-{s,t}, f (u,v) cannot exceed its edge capacity,
so residual capacity is r(u,v) = c(u,v) - f (u,v), if r(u,v) =
0, then we call the edge (u,v) is saturated.
(3) Excess flow: Σ f (v,u) = excess(u) > 0 for all u, v
belong to V-{s}, we say excess(u) is the summation of
flows into the node u. We say that the node u is over-
flowing if excess(u) > 0.
We conduct the network flow approach to find the
maximum flow between dummy source and sink nodes.
First, we apply the shortest path algorithm [34] to calcu-
late the distance between each node to the dummy sink
node and set the shortest distance as the height of node.
Take an example in Figure 2, the initial height of the
node G1 is 2 because the shortest path between node
G1 and dummy sink node T is 2. Second, the dummy
source node starts to push the flow to its neighbors.
While there exists a flow into the node u which denoted
as excess(u) to be larger than zero, we can do “push”
operation from node u to its neighbor node v based on
the height label of the node. If the height of current
node u is equal or less than the height of its neighbor
node v, we set the height of node u as one more than
the height of the neighbor node v (i.e. h(u) h(v) +1).
Therefore, if the node u has excess flow and the height
of a node equal or less than its neighbors (i.e. h(u)ᒭh(v))
while the residual capacity is greater than zero (i.e. r(u,
v) > 0), we apply “relabel” operation to increase the
height of the current node and push the flow from node
u to node v. The node with positive excess flow is
termed an active node and we select an active node and
conduct the “push” and “relabel” operations to give the
flow to dummy sink node repeatedly until there is no
more active node. Finally, we run this procedure for
each 322 candidate proteins and sort them based on the
maximum flow. We supposed there be a probability
density function of the maximum flow of the single can-
didate protein and there be parameters that can maxi-
mize the likelihood function to fit the density function.
A simple and rapid method to calculate an approximate
confidence interval is based on the application of the
central limit theorem. We get the mean and variance to
calculate the top 5% area as lower limits of the 95
th per-
centile confidence interval in the distribution of the
maximum flow.
On the other hand, the inhibition of some proteins
may also deactivate some non-disease genes and this
might damage the normal functionalities of networks as
undesirable side effects. In the procedure of the network
flow approach, the flow may pass through the non-dis-
ease genes with different paths in the network and we
simultaneously calculate those non-disease genes nodes
using Equation (2) and (3) based on all the nodes
retrieving a flow and their neighborhood nodes [35].
Pi = Fi

Ki (2)
AG(Dm)=

i=1
Pi (3)
where Pi is the affected ratio of a node i in which Ki is
the total number of incoming neighbors of the node i
and Fi is the number of neighbors of node i which push
the flow to node i. AG(Dm) denotes the total affected
genes of candidate proteins which is the sum of affected
ratio Pi’so fa l lt h en o d e sw h i l er u n n i n gt h em a x i m u m
flow procedure on the m
th candidate proteins.
We take an example to illustrate a small directed
edge-weighted network using our method in Figure 2.
We define gene G6 and G7 as disease genes and create
a dummy sink node T to capture the flow from the
gene G6 and G7. To illustrate, the infinite flow is com-
ing from the G1, the flow between G1 and G3 limit to
0.69 due to the edge capacity. On the other hand, the
edge capacity between G3 and G7 is 0.9 but the flow
from G3 only have 0.69 can pass to node G7. The flow
from G7 to T is by the same reason. The detailed proce-
dure of our method is shown in Table 1. We calculate
candidate protein G1 of drug D1 with the maximum
flow 2.52 to both disease gene G6 and G7 using our
method. This procedure denotes that if one of the edge
capacities is small and it will limit the flow in the whole
path. If there are more paths between candidate proteins
and disease genes, the maximum flow may be larger.
Since the number of incoming degrees of G1, G3, G6
and G7 are all 2 (Ki = 2) and each node receives flow
Figure 2 Sample networks for the maximum flow and affected
genes.
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ple, gene G3 has two incoming edges from node G1 and
G2 but only gene G1 pushes flow to G3. So, we calcu-
late each of the Pi for G1, G3, G6 and G7 is 0.5 based
on Equation (2) and AG(D1) = 2 based on Equation (3)
respectively. For single candidate protein G2, we can
similarly compute its maximum flow as 3.17 and the
AG(D2) = 6. We note that the flow of candidate protein
G2 is greater than that of gene G1, so drug D2 may be
more effective than drug D1.
Experiments
Prostate cancer is a frequently diagnosed as a hormone
refractory and aggressive metastasis cancer and there is
a pressing need for the development of new treatments.
Prostate cancer frequently progresses from an androgen
dependent disease but it can also transit to the androgen
independent disease which is useless for taking andro-
gen ablation therapy. We use prostate cancer as our test
domain and integrate microarray data taken from [36]
that consists of 62 primary tumors and 41 normal tis-
sues from Stanford Microarray Database (SMD) [37].
DrugBank is the database that collects all FDA approved
drugs and their targets and it contains 3516 drugs and
1046 drug targets. Most of the drugs have only one tar-
get and most genes are targeted by more than one drug.
There are 16 overlapped genes between candidate pro-
teins and truly prostate cancer genes and those genes
only link to the dummy source node based on the con-
straint 4. We get 20 drug targets which belong to the
“approved” and not “nutraceutical” drugs for prostate
cancer in DrugBank and nine drug targets are also in
t h em i c r o a r r a yd a t at ob eo u rt e s t e db e n c h m a r k .W e
implement our methods in java programming language
with CPU Intel 1.73GHz and 1GB main memory run-
ning under the windows operating system.
Single drug target discovery by maximum flow approach
We show the distribution of the maximum flows
obtained from the 322 candidate proteins in Figure 3
and the detail information of the maximum flow and
affected genes of each candidate protein see Additional
file 2. We display 22 candidate proteins at the top 5%
maximum flow as lower limits of the 95
th percentile
confidence interval in Table 2. The candidate protein
with the highest maximum low has at least node degree
30 is 14/22 (64%) and as a result hubs may be also con-
sidered for further evaluation as being potential drug
targets [38].
Although the biological validation for the predicated
results from our method is difficult, it turns out that
some of our predicted results had been reported in the
public literature for validation. Our approaches find
androgen receptor (AR) which has the rank 1 in our
results and suitable for androgen-deprivation therapy in
prostate cancer [39]. Casodex, Eulexin, Striant Bucl all
use AR to be their drug targets. Erlotinib, a tyrosine
kinase inhibitor targeted EGFR, is known to be over-
expressed in prostate cancer and clinical showed that
the inhibition of EGFR has implicit antitumor effects in
prostate cancer [40,41]. CASP-3 and -7 are critical genes
involved in cytokin and apoptosis interactions and they
are also potential drug targets for cancer [42]. However,
the drug target CASP3 is strongly related to several dis-
eases and it is hard to use as a specific property to dis-
tinguish the prostate cancer. The membrane receptors
and related genes of TGFB are associated with tumor
suppressor functions for controlling cell apoptosis in the
progression of prostate cancer and it is also related to
promote disease progression of prostate cancer. Inhibi-
tion of TGFB has been shown to suppress the growth of
androgen-independent tumors and it might be a valu-
able therapeutic strategy for androgen-independent dis-
ease [43]. Our approaches also identify gene IGF1R
which is annotated as a best known family of cell signal-
ing molecules and have already been cited in the clinical
drug development [44]. Major pharmaceutical compa-
nies which focus on treatment of the hormone refrac-
tory prostate cancer also develop the drug antisense
inhibitor ATL1101 with drug target IGF1R to treat the
human cancer and it has already shown in laboratory
studies with potential activity of inhibiting programmed
Table 1 The detailed procedure of our method on drug
target G1
Step Push node flow Received node
1S∞ G1
2 G1 1.83 G6
3 G1 0.69 G3
4 G3 0.69 G7
5 G6 1.83 T
6 G7 0.69 T
Figure 3 the distribution of the maximum flow of single drug
target.
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the mutation in PTPN11 gene leads to the SHP2 var-
iants and transits the signals of the mitogenic and pro-
migratory via the activation of the RAS/ERK cascade.
SHP2 is also the key target of the oncogenes which is
also shown to affect the cell proliferation and neu-
induced transformation in mouse modes and the inhibi-
tion of the SHP2 offers the potential new therapeutic
avenues in the cancer [46]. Other researches and our
method both suggested that Marimastat is a MMP2
inhibitor which may have effective biological activities
for prostate cancer [47]. AURKA kinases are strongly
expressed that are related to the wide range of the can-
cer types and their expressions are also associated with
the gene amplification in tumor cell, genetic instability
and poor prognosis [48]. AURKA is related to the G2-M
transition in the cell cycle and the inhibition of this
gene may lead to the G2-M arrest and apoptosis [48].
Inhibitor of monoamine oxidase A (MAOA) is com-
monly used to treat the neurological conditions and
other researchers identified the higher expression
MAOA in prostate cancer comparing with the normal
cell [49]. Our findings suggest that the inhibitors of
M A O Am a yb ea na n t i - o n c o g e n i ct h e r a p yf o rp r o s t a t e
cancer and the results are consistency with the recent
experimental results. The HER2/neu (ERBB2) oncogene
plays an important role in hormone-related cancer asso-
ciated with the prostate cancer and previous clinical
studies showed that the effects of inhibitor of ERBB2
tyrosine kinase activity inhibit PC-3 cell growth [50].
The research reported that K252a with drug target MET
inhibits the proliferation of the androgen-independent
human prostate carcinoma cell line and it causes the
change of the cell cycle [51]. There are 4 disease genes
(AR, EGFR, ESR1, and ERBB2) to be potential drug tar-
gets in our top 22 candidate proteins of the 95
th percen-
tile confidence interval and it show that the truly
prostate cancer genes do not always direct to the drug
targets.
We define set of the truly drug targets which are
annotated for prostate cancer drugs deposited in Drug-
Bank database [28] and other drug targets are regarded
as non-prostate cancers drug targets. Figure 4 shows the
maximum flow between them and the results show our
method can screen out potential drug targets for pros-
tate cancers with higher maximum flow.
The effect of the partially-directed and directed graph in
our method
The network we use is only partially directed graph and
we conduct experiments to compare the performances
of our methods against both partially directed and direc-
ted graphs. We randomly assign each undirected edge
with a direction so that its corresponding partially direc-
ted graph can be transferred into a directed graph. Fig-
ure 5 shows the distributions of the maximum flow of
Table 2 Top 22 single drug targets for prostate cancer
Drug name Target Name F(Du) AG(Du)
Casodex, Eulexin, Striant Bucl AR 45.88 5576.87
Erlotinib EGFR 29.54 4272.24
Budesonide NR3C1 12.52 4677.47
Estramustine ESR1 10.88 4597.53
5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid CASP3 10.84 3914.63
Glycerol TGFBR2 10.40 2943.79
ATL1101 IGF1R 10.29 4080.81
Dodecane-Trimethylamine PTPN11 8.43 3678.47
Fica CASP7 7.80 3276.11
Diphenylacetic Acid CTSB 6.62 3391.85
Marimastat MMP2 6.29 3518.70
SLC25A6 5.75 3994.49
AURKA 5.60 3256.80
Phenelzine MAOA 5.40 3067.25
LGALS3BP 5.34 2902.46
LCK 5.22 3607.57
THBS1 5.10 2451.01
Insulin, porcine INSR 4.32 2344.82
Trastuzumab ERBB2 4.31 3351.47
Staurosporine CDK2 4.00 3692.15
K-252a MET 3.90 2318.86
TFRC 3.83 2611.10
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network and its corresponding transferred directed net-
work. The similar trends in both graphs do not seem to
affect the effectiveness of our approach using partially
directed interaction data. Figure 6 denotes the regres-
sion to calculate the trend line for the maximum flow
against candidate proteins while x-axis represents the
identification number of the candidate proteins and y-
axis represents the log of maximum flow. The fitting
function of the overall maximum flow in partially-direc-
ted graph is y = -2.929ln(x)+15.066 and those in direc-
ted graph is y = -1.139ln(x)+5.7863. The distributions of
those two graphs are similar but the partially directed
graph tends to provide a much higher maximum flow
for the disease genes. It implies that the flow can use
different paths to reach the disease-related genes by pas-
sing the bi-direction edges in the partially directed graph
while the directed graph may restrict the flow to reach
the disease genes.
The performance of our method
We use the same test data to show the performance
between our method and the previous approaches such
as degree, network entropy, betweenness, closeness and
random walk. Degree centrality is defined as the number
of links incident upon a node and rank genes based on
their degree. Another network attribute called network
entropy which is a characteristic measure of topology
configuration based on the degree distribution [52] and
this is consistent with the Shannon entropy of the distri-
bution [53]. Closeness centrality is the normalized num-
ber of steps to access every other node from a given
node in a network by calculating the geodesic distance
of every node to every other node. Betweenness central-
ity denotes the fraction of the nodes occur in the short-
est paths comparing with the other nodes. Otherwise,
we apply the same scoring function as Equation (1) to
assign the weight to the edges and calculated between-
ness and closeness by JUNG toolkit [54]. Besides the
closeness/betweenness centrality modeled by the use of
shortest paths, Random walk capture more all type of
communication scenarios and denotes the fraction of
time spent ‘visiting’ the node through the edges in the
network [55]. We use candidate proteins as start nodes
to apply Random walk with alpha value 0.3 and sum up
the probability of disease genes to rank the candidate
proteins.
Previous study showed that precision-recall curves
g i v eam o r ei n f o r m a t i v eo fa na l g o r i t h m ’s performance
based on the skewed degree-distributions of the scale-
free biological network [56]. Precision is defined as the
fraction of truly drug targets identified among the candi-
date proteins ranked above the particular position,
whereas recall is defined as the fraction of truly drug
targets identified among total number of the truly drug
targets. We plot average precision vs. recall level curves
by varying the rank of a candidate protein to be consid-
ered a truly drug target in Figure 7. We obtain the high-
est mean average precision as 0.31 and the results show
that our method outperforms all other methods. The
results based on the statistical t-test method denotes
Figure 4 the maximum flow between prostate cancer and non-
prostate cancer.
Figure 5 the distribution of the maximum flow between
partially directed and directed graph.
Figure 6 the maximum flow of each drug target between
partially directed and directed graph.
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Page 8 of 11that only dependent on the gene expression values with-
out network information supported is not suitable to
discover the potential drug targets and genes to be true
drug targets may have small differential expression
changes. Unfortunately, it turns out that attributes of
the network topology are not strongly correlated to the
lethality of removing the associated protein from the
network due to the noise in the interaction network
[17].
In particular, we also compare these methods in terms
of the average rank of the truly drug targets. Clearly,
lower average rank indicates better performance. We
report the percentage of truly drug target that are ranked
in the top 1% of all candidate proteins (practically in the
top 3 genes), in the top 3% (practically in the top 10
genes) and in the top 15% (practically in the top 48
genes) among all candidate. The absolute count and aver-
age position (AP) of found truly drug target is presented
in Table 3. For instance, in the top 1%, there is a tie
between degree and our method, where both find 2 truly
drug targets. However, degree has AP of 2.5 which is
larger than those of our method. In the top 15%, our
method can find largest number of truly drug targets and
also get lower AP than closeness and random walk
method which get less number of truly targets.
Conclusion
In this paper, we formulate the identification of drug
target prediction as a maximum flow problem on biolo-
gical networks. Previously, maximum flow approach is
applied to do the graph cut which is popular related to
computer vision research area and it separates the
sources and targets in the network. To our knowledge,
there are no computational methods that use the idea of
maximum flow to predict potential drug target for spe-
cific disease treatment before this work. We successfully
identify potential drug targets which are strongly related
to the existing well known drugs for prostate cancer
treatment and also discover more potential drug targets
that could attract the attention to biologists. Our meth-
ods do not know the real ideal routes in the disease net-
w o r kb u tt r yt of i n dt h ef e a s i b l ef l o wt og i v eas t r o n g
influence to the disease genes through possible paths
using maximum flow approach. A significant difference
between our method and random walk is the way that
we treat the length of the path searched in the network.
Random walk is more sensitive to the length of the
paths with its matrix multiplication. The reason why we
exclude the metabolic pathways in the networks is that
it is hard to measure the whole kinetic parameters in a
metabolic pathway towards disrupting the function.
However, it is possible to extend our network between
proteins and chemical compounds to representation of
metabolic pathways.
Additional material
Additional file 1: List of the prostate cancer genes. We use 108
genes from OMIM, KEGG pathway database, PGDB database as the truly
prostate cancer related genes.
Additional file 2: The maximum flow and affected genes of 322
candidate proteins. The maximum flow and affected genes of 322
candidate proteins.
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